Glucagon antagonists

A method of treating one or more symptoms of a disease responsive to the modulation of a glucagon receptor in a subject, comprising administering to a subject in need thereof a compound of Formula I:

• wherein
• R44 is H, CH3 or CH3CH2;
• R45 is C1-6-alkyl, alkenyl, alkoxy, C3-6-cycloalkyl, C4-8-cycloalkenyl, C4-8-bicycloalkenyl, aryl or heteroaryl, any of which can be optionally substituted with one or more substituents selected from C1-6alkyl, CF3, F, CN or OCF3;
• L is phenyl, indenyl, benzoxazol-2-yl, C3-6-cycloalkyl, C4-8-cycloalkenyl or C4-8-bicycloalkenyl, any of which can be optionally substituted with one or more substituents selected from F, Cl, CH3, CF3, OCF3 or CN;
• and
• R46 represents one or more substituents selected from H, F, Cl, CH3, CF3, OCF3 or CN;
• or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

A method of treating one or more symptoms of a disease responsive to a decrease in the hepatic glucose production or in the blood glucose level of a subject, comprising administering to a subject in need thereof a compound of Formula I:

• wherein
• R44 is H, CH3 or CH3CH2;
• R45 is C1-6-alkyl, alkenyl, alkoxy, C3-6-cycloalkyl, C4-8-cycloalkenyl, C4-8-bicycloalkenyl, aryl or heteroaryl, any of which can be optionally substituted with one or more substituents selected from C1-6alkyl, CF3, F, CN or OCF3;
• L is phenyl, indenyl, benzoxazol-2-yl, C3-6-cycloalkyl, C4-8-cycloalkenyl or C4-8-bicycloalkenyl, any of which can be optionally substituted with one or more substituents selected from F, Cl, CH3, CF3, OCF3 or CN;
• and
• R46 represents one or more substituents selected from H, F, Cl, CH3, CF3, OCF3 or CN;
• or a pharmaceutically acceptable salt, solvate, or prodrug thereof.